Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPA1 | O60313 | 1/20 | 0.48 |
| ▸ | EIF5B | O60841 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 3/20 | 0.48 |
| ▸ | CCND1 | P24385 | 3/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | PRKACG | P22612 | 1/20 | 0.47 |
| ▸ | PRKACB | P22694 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 14/20 | 0.44 |
| ▸ | GSK3B | P49841 | 14/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224940 | 0.87 | CDK4 (0.61) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6332914 | 0.86 | CDK4 (0.54) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6325230 | 0.84 | CDK4 (0.54) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6329959 | 0.84 | CDK4 (0.60) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6332262 | 0.83 | CDK4 (0.68) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6327738 | 0.82 | CDK4 (0.46) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6324920 | 0.81 | CDK4 (0.67) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL6334166 | 0.81 | CDK4 (0.59) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL2881681 | 0.80 | CDK4 (0.54) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL2343710 | 0.80 | CDK4 (0.63) | OPA1EIF5BMETHMOX2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | OPA1 1919/4885EIF5B 1203/4885MET 509/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | OPA1 1798/4885EIF5B 1247/4885MET 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.